Literature DB >> 25412960

Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells.

Jianlin Wang1, Xisheng Yang, Bai Ruan, Bin Dai, Yuan Gao, Juanli Duan, Shibin Qu, Kaishan Tao, Kefeng Dou, Haimin Li.   

Abstract

Due to high incidence of invasion and intrahepatic metastasis, hepatocellular carcinoma (HCC) is one of the most aggressive tumors in the world, which is also associated with the acquisition of epithelial-mesenchymal transition (EMT). Increasing evidence suggests that cancer cells with EMT traits share many biological characteristics with cancer stem cells. And miR-200a has been known as a powerful regulator of EMT. Here, we sought to investigate the role of miR-200a in regulation of EMT phenotype of liver cancer stem cells (LCSCs). We used side population (SP) sorting to obtain cancer stem-like cells from HCC cell lines and identified that the SP fraction could be enriched with LCSCs. Then, we detected the expression of miR-200a and EMT makers in SP and non-SP cells. Our results suggested that miR-200a was down-regulated in SP cells, along with relatively low epithelial marker and high mesenchymal marker. In order to find the role of miR-200a in the manipulation of EMT, we transfected miR-200a mimic into LCSCs and found that overexpression of miR-200a resulted in down-regulation of N-cadherin, ZEB2, and vimentin, but up-regulation of E-cadherin. Moreover, overexpression of miR-200a resulted in decreased migration and invasion ability in LCSCs. In conclusion, our study revealed that miR-200a played an important role in linking the characteristics of cancer stem cells with EMT phenotype in HCC, and targeting miR-200a might be an effective strategy to weaken the invasive behavior of LCSCs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25412960     DOI: 10.1007/s13277-014-2856-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  54 in total

1.  Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.

Authors:  Yohei Shimono; Maider Zabala; Robert W Cho; Neethan Lobo; Piero Dalerba; Dalong Qian; Maximilian Diehn; Huiping Liu; Sarita P Panula; Eric Chiao; Frederick M Dirbas; George Somlo; Renee A Reijo Pera; Kaiqin Lao; Michael F Clarke
Journal:  Cell       Date:  2009-08-07       Impact factor: 41.582

Review 2.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

3.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.

Authors:  Teh-Ia Huo; Han-Chieh Lin; Yi-Hsiang Huang; Jaw-Ching Wu; Jen-Huei Chiang; Pui-Ching Lee; Shou-Dong Lee
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 8.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

9.  MicroRNAs involved in neoplastic transformation of liver cancer stem cells.

Authors:  Ren Li; Niansong Qian; Kaishan Tao; Nan You; Xinchuan Wang; Kefeng Dou
Journal:  J Exp Clin Cancer Res       Date:  2010-12-23

10.  The molecular pathogenesis and clinical implications of hepatocellular carcinoma.

Authors:  Makoto Meguro; Toru Mizuguchi; Masaki Kawamoto; Koichi Hirata
Journal:  Int J Hepatol       Date:  2011-12-04
View more
  9 in total

1.  MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells.

Authors:  Wei-Feng Yao; Jun-Wei Liu; Dong-Sheng Huang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

Review 2.  MicroRNA regulation of liver cancer stem cells.

Authors:  Weiyang Lou; Jingxing Liu; Yanjia Gao; Guansheng Zhong; Bisha Ding; Liang Xu; Weimin Fan
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

3.  MiR-15a suppresses hepatocarcinoma cell migration and invasion by directly targeting cMyb.

Authors:  Bo Liu; Ting Sun; Gang Wu; Hui Shang-Guan; Zhao-Jin Jiang; Ji-Ren Zhang; Yan-Fang Zheng
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Downregulation of transcription factor TCTP elevates microRNA-200a expression to restrain Myt1L expression, thereby improving neurobehavior and oxidative stress injury in cerebral palsy rats.

Authors:  Xiaoxia He; Zibo Liu; Yatao Pang; Wei Xu; Long Zhao; Hongling Li
Journal:  Cell Cycle       Date:  2020-03-15       Impact factor: 4.534

Review 5.  The Role of MicroRNAs in the Regulation of Gastric Cancer Stem Cells: A Meta-Analysis of the Current Status.

Authors:  Vitalba Ruggieri; Sabino Russi; Pietro Zoppoli; Francesco La Rocca; Tiziana Angrisano; Geppino Falco; Giovanni Calice; Simona Laurino
Journal:  J Clin Med       Date:  2019-05-09       Impact factor: 4.241

Review 6.  Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.

Authors:  Na Li; Ying Zhu
Journal:  Therap Adv Gastroenterol       Date:  2019-01-22       Impact factor: 4.409

Review 7.  Genetic And Epigenetic Regulation Of E-Cadherin Signaling In Human Hepatocellular Carcinoma.

Authors:  Xiaoxiao Fan; Shengxi Jin; Yirun Li; Parikshit Asutosh Khadaroo; Yili Dai; Lifeng He; Daizhan Zhou; Hui Lin
Journal:  Cancer Manag Res       Date:  2019-10-16       Impact factor: 3.989

Review 8.  The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells.

Authors:  Sabrina Bimonte; Maddalena Leongito; Antonio Barbieri; Vitale Del Vecchio; Michela Falco; Aldo Giudice; Raffaele Palaia; Vittorio Albino; Raimondo Di Giacomo; Antonella Petrillo; Vincenza Granata; Francesco Izzo
Journal:  Stem Cells Int       Date:  2016-03-28       Impact factor: 5.443

Review 9.  Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy.

Authors:  Yafei Wu; Jigang Zhang; Xue Zhang; Heming Zhou; Gaolin Liu; Qin Li
Journal:  Front Pharmacol       Date:  2020-03-06       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.